Afatinib Dimaleate Intermediate CAS 314771-76-1 Purity >99.0% (HPLC) Factory

Short Description:

Chemical Name: (S)-N4-(3-Chloro-4-Fluorophenyl)-7-((Tetrahydrofuran-3-yl)oxy)quinazoline-4,6-Diamine

CAS: 314771-76-1

Purity: >99.0% (HPLC) 

Appearance: Light Yellow to Yellow Powder

Intermediate of Afatinib Dimaleate (CAS: 850140-73-7) 

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name (S)-N4-(3-Chloro-4-Fluorophenyl)-7-((Tetrahydrofuran-3-yl)oxy)quinazoline-4,6-Diamine
Synonyms N4-(3-Chloro-4-Fluorophenyl)-7-[[(3S)-Tetrahydro-3-Furanyl]oxy] -4,6-Quinazolinediamine; Afatinib Impurity B; Afatinib-des(4-Dimethylamino-2-en-1-oxo)butyl; Des(4-Dimethylamino-2-en-1-oxo)butyl Afatinib
CAS Number 314771-76-1
CAT Number RF-PI2028
Stock Status In Stock, Production Capacity 100MT/Year
Molecular Formula C18H16ClFN4O2
Molecular Weight 374.8
Boiling Point 559.0±50.0℃
Density 1.473±0.060 g/cm3
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance Light Yellow to Yellow Powder
Identification The Retention Time of Principal Peak in HPLC Should Correspond to the Standard
Purity / Analysis Method >99.0% (HPLC)
Loss on Drying <0.50%
Residue on Ignition <0.20%
Single Impurity <0.50%
Total Impurities <1.00%
Heavy Metals (as Pb) ≤20ppm
Test Standard Enterprise Standard
Usage Intermediate of Afatinib Dimaleate (CAS: 850140-73-7)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

1

FAQ:

Application:

(S)-N4-(3-Chloro-4-Fluorophenyl)-7-((Tetrahydrofuran-3-yl)oxy)quinazoline-4,6-Diamine (CAS: 314771-76-1) is an intermediate of Afatinib Dimaleate (CAS: 850140-73-7). Afatinib is the second-generation potent and irreversible dual inhibitor of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinase, developed by Boehringer Ingelheim, Germany. It is capable of irreversibly inhibiting the activity of the tyrosine kinase by undergoing the Michael reaction with the thiol group of cysteine at position 797 of the EGFR. Function: 1. Like Lapatinib and Neratinib, Afatinib is a protein kinase inhibitor that also irreversibly inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases. 2. Afatinib is not only active against EGFR mutations targeted by first generation TKIs like erlotinib or gefitinib, but also against mutations such as T790M which are not sensitive to these standard therapies. Because of its additional activity against Her2, it is being investigated for breast cancer as well as other EGFR and Her2 driven cancers. 3. Afatinib is a drug for the first-line treatment of patients with distinct types of metastatic (EGFR mutation positive) non-small cell lung carcinoma (NSCLC). It acts as an irreversible covalent inhibitor of the receptor tyrosine kinases epidermal growth factor receptor (EGFR) and erbB-2 (HER2).

  • Write your message here and send it to us